Phlyctenular keratoconjunctivitis is an inflammatory syndrome caused by a delayed (aka type-IV) hypersensitivity reaction to one or more antigens. The triggering antigen is usually a bacterial protein (particularly from Staphylococcus aureus), but may also be a virus, fungus (particularly Candida albicans), or nematode. Symptoms
Irritation 
Discomfort or pain 
Foreign-body sensation 
Tearing 
Blepharospasm
Photophobia
Mucopurulent discharge (rarely) In cases where the cornea is affected, pain and photophobia are more likely, and corneal scarring can occur (potentially impairing vision). Presentation
The syndrome is marked by the appearance of characteristic lesions, known as phlyctenules, on the cornea and/or conjunctiva. These usually manifest as small (1 - 3 or 1 - 4 mm) raised nodules, pinkish-white or yellow in color, which may ulcerate (or, more rarely, necrose) and are often surrounded by dilated blood vessels. Corneal lesions are usually triangular in shape, with the base at the limbus and the apex pointing towards the center of the cornea. Diagnosis
Clinical findings of Corneal lesion or  corneal ulceration. Treatment
The symptoms of phlyctenular keratoconjunctivitis are primarily treated with application of an appropriate corticosteroid eye drop, such as prednisolone acetate (Pred Forte) or loteprednol (Lotemax). Loteprednol is increasingly preferred due to its lower risk of elevating intraocular pressure. The corticosteroid suppresses the immune response, reducing inflammation and improving most symptoms.The causative agent (i.e. the source of the antigen that triggered the hypersensitive immune response) should also be identified. Staphylococcus aureus is usually the primary suspect, along with Mycobacterium tuberculosis in areas where TB is endemic, followed by Chlamydia trachomatis.
Mefloquine, sold under the brand name Lariam among others, is a medication used to prevent or treat malaria. When used for prevention it is typically started before potential exposure and continued for several weeks after potential exposure. It can be used to treat mild or moderate malaria but is not recommended for severe malaria. It is taken by mouth.Common side effects include vomiting, diarrhea, headaches, sleep disorders, and a rash. Serious side effects include potentially long-term mental health problems such as depression, hallucinations, and anxiety and neurological side effects such as poor balance, seizures, and ringing in the ears. It is therefore not recommended in people with a history of mental health problems or epilepsy. It appears to be safe during pregnancy and breastfeeding.Mefloquine was developed by the United States Army in the 1970s and came into use in the mid-1980s. It is on the World Health Organizations List of Essential Medicines. It is available as a generic medication. Medical uses
Mefloquine is used to both prevent and treat certain forms of malaria. Malaria prevention
Mefloquine is useful for the prevention of malaria in all areas except for those where parasites may have resistance to multiple medications, and is one of several anti-malarial medications recommended by the United States Centers for Disease Control and Prevention for this purpose. It is also recommended by the Infectious Disease Society of America for malaria prophylaxis as a first or second-line agent, depending on resistance patterns in the malaria found in the geographic region visited.